PW Medtech Group Limited provided earnings guidance for the year ended December 31, 2023. The Group is expected to record (i) a net profit in the range of RMB 192 million to RMB 215 million for the year ended December 31, 2023, representing an increase of 49% to 67% as compared to that of approximately RMB129 million for the year ended December 31, 2022, and (ii) a profit attributable to owners of the Company in the range of RMB 142 million to RMB 165 million for the year ended December 31, 2023, representing an increase of 33% to 55% as compared to that of approximately RMB 106 million for the year ended December 31, 2022. Such increase is primarily due to a significant increase in the profit contributed by the Group's blood purification business and the infusion set business.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.95 HKD | 0.00% | 0.00% | +15.85% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+15.85% | 190M | |
+11.84% | 27.79B | |
-32.98% | 2.98B | |
-15.97% | 2.52B | |
+11.90% | 2.34B | |
-1.11% | 1.91B | |
-13.37% | 1.83B | |
-7.78% | 1.39B | |
-0.38% | 1.27B | |
+4.01% | 1.13B |
- Stock Market
- Equities
- 1358 Stock
- News PW Medtech Group Limited
- PW Medtech Group Limited Provides Earnings Guidance for the Year Ended December 31, 2023